Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

HyperCVAD regimen

View Patient Information

A regimen consisting of cyclophosphamide, vincristine, doxorubicin and dexamethasone, administered on a hyperfractionated schedule that is used to treat adult acute lymphoblastic leukemia (ALL) or Burkitt-type ALL and adult small non-cleaved cell (Burkitt) lymphoma, AIDS-related B-cell lymphomas, blastic plasmacytoid dendritic cell neoplasm (BPDCN) and T-cell lymphomas.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	Hyper-CVAD regimen hyperfractionated cyclophosphamide-vincristine-adriamycin-dexamethasone regimen
Abbreviation:	HyperCVAD

HyperCVAD regimen

Search NCI's Drug Dictionary